Skip to content

Uniportal Versus Triportal Thoracoscopic Lobectomy and Sublobectomy for Early Stage Lung Cancer

Uniportal Versus Triportal Thoracoscopic Lobectomy and Sublobectomy for Early Stage Lung Cancer: a Multicenter Randomized Controlled Trial

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02933294
Enrollment
356
Registered
2016-10-14
Start date
2015-05-31
Completion date
2020-12-31
Last updated
2016-10-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung Neoplasms

Keywords

uniportal, lung cancer, VATS

Brief summary

Lung cancer is one of the most common cancers in the world. At present, surgical resection is still the standard treatment for early stage lung cancer. Triportal thoracoscopic lung resection is a routine surgically procedure for early stage lung cancer while uniportal thoracoscopic lung resection is developing rapidly in recent years. Although uniportal VATS pulmonary resection has been proven to be effective in preventing postoperative morbidities, there is still no ample evidences to demonstrate that uniportal VATS pulmonary resection is equal or superior to traditional triportal thoracoscopic pulmonary resection. The purpose of this multicenter randomized controlled trial study is to compare the uniportal VATS with traditional triportal VATS pulmonary resection in postoperative complications, long-term survival, lymph node dissection and local recurrence.

Detailed description

Lung cancer is one of the most common cancers in the world,especially in China, where the mortality ranked first in malignant tumors whether for males or females. At present, VATS (Video-assisted thoracoscopic surgery) lobectomy is still the gold standard for the treatment of lung cancer. Triportal thoracoscopic lung resection is a routine surgically procedure for early stage lung cancer while uniportal thoracoscopic lung resection is developing rapidly in recent years. Retrospective study in recent years showed that the postoperative complication rate is similar between uniportal thoracoscopic surgery and triportal thoracoscopic surgery. Meanwhile, the incision is more pleasing, the inflammatory response may be milder and the hospitalization time may be shorter in the uniportal thoracoscopic surgery. But until now there is no result of the randomized controlled study on the effectiveness and the prognosis between uniportal thoracoscopic surgery and triportal thoracoscopic surgery to support this conclusion. The objective of this multicenter randomized controlled trial study is to compare the postoperative complications, long-term survival, local recurrence, other perioperative variables such as conversion rate, blood loss, lymph nodes retrieved and postoperative hospital stay between the triportal VATS pulmonary resection and uniportal VATS pulmonary resection on early stage lung cancer.

Interventions

PROCEDURETriportal pulmonary resection surgery

Uniportal video-assisted thoracoscopic surgery

PROCEDUREUniportal pulmonary resection surgery

Triportal video-assisted thoracoscopic surgery

Sponsors

Sun Yat-sen University
CollaboratorOTHER
Fudan University
CollaboratorOTHER
Chinese PLA General Hospital
CollaboratorOTHER
Beijing Chest Hospital
CollaboratorOTHER
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* age≥18 years; * cT1- 2N0-1M0 diagnosed by chest CT, PET-CT before operation; * No severe comorbidity, can tolerate anesthesia; * ECOG PS scores≤2; * The patients sign informed consents by themselves.

Exclusion criteria

* Inability to tolerance of tracheal intubation and general anesthesia; * ECOG PS scores\>2; * Severe comorbidities including: Angina occurs in 3 months, uncontrolled hypertension, Congestive heart failure, a history of myocardial infarction in 6 months before admission, severe arrhythmia, severe liver, kidney or other metabolic diseases.

Design outcomes

Primary

MeasureTime frameDescription
Postoperative respiratory complications30 days after surgeryThese respiratory complications involve respiratory distress or failure after the operation with continuation of mechanical ventilation, pulmonary atelectasis requiring sputum suction by bronchoscopy, pneumonia requiring specific antibiotics confirmed by thoracic X-ray or CT scan of the thorax and a positive sputum culture, and acute respiratory distress syndrome.

Secondary

MeasureTime frameDescription
Blood lossIntraoperationblood loss during the surgery
Lymph node dissectionIntraoperationDuring the surgery, lymph node dissection were performed. The number of removed lymph-nodes were recorded according to the postoperative pathological diagnosis, and the stations of the lymph node were recorded according to the International Association for the Study of Lung Cancer (IASLC) Lymph Node Map.
Long term survival5 yearfive-year survival rates after surgery
Local recurrence3 yearsthree-year local recurrence rate after surgery
Conversion rateIntraoperationconversion to thoracotomy during surgery

Countries

China

Contacts

Primary ContactJuwei Mu, MD
mujuwei@cicams.ac.cn8610-87788495

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026